Premium
Citalopram dose reductions in response to safety warning increased hospitalization
Publication year - 2016
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30166
Subject(s) - citalopram , medicine , food and drug administration , veterans affairs , emergency medicine , unintended consequences , medical emergency , psychiatry , anxiety , political science , law , antidepressant
A group of Department of Veterans Affairs (VA) patients who had their citalopram doses reduced after a federal safety communication about doses exceeding 40 mg/day experienced a significant increase in hospitalizations and deaths compared with patients whose doses were not reduced, a study has found. The study's authors suggested that the Food and Drug Administration's (FDA's) 2011 safety communication appears to have generated unintended clinical consequences. Study results were published online May 10 in the American Journal of Psychiatry .